Abstract: Disclosed herein are standardized and optimized, modular single-use kits and methods for sterile or non-sterile preparation of biological material, such as cells or tissue, for immediate use, further preparation, or storage. These single-use kits comprise at least one single-use component necessary for the preparation of biological material in accordance with a particular method as set forth in the instructions for use included with each particular type of single-use kit that set forth a unique method for using that particular type of single-use kit. The single-use kit of the invention comprises at least one modular, single-use packaging frame wherein at least one modular, single-use tray with an identifying is disposed, wherein at least one single-use component is organized. The identifying label on each modular single-use tray corresponds to (correlates with) a sequence of steps set forth in the instructions included with each single-use kit.

Abstract: Disclosed herein are standardized and optimized, modular single-use kits and methods for sterile or non-sterile preparation of biological material, such as cells or tissue, for immediate use, further preparation, or storage. These single-use kits and methods facilitate and improve a healthcare practitioner's ability to prepare biological material for research, diagnostic and therapeutic purposes in a convenient, consistent, repeatable, safe and effective manner.

Abstract: Disclosed herein are standardized and optimized, modular single-use kits and methods for sterile or non-sterile preparation of biological material, such as cells or tissue, for immediate use, further preparation, or storage. These single-use kits and methods facilitate and improve a healthcare practitioner's ability to prepare biological material for research, diagnostic and therapeutic purposes in a convenient, consistent, repeatable, safe and effective manner.

Abstract: The invention provides a cardiovascular occluder for treating a cardiovascular abnormality comprising a frame and an alarmin or an alarmin activator bound to the surface of the frame. The invention further provides methods of manufacturing the cardiovascular occluder and methods of treating cardiovascular abnormalities by delivering the cardiovascular occluder.

Abstract: The invention provides a cardiovascular occluder for treating a cardiovascular abnormality comprising a frame and an alarmin or an alarmin activator bound to the surface of the frame. The invention further provides methods of manufacturing the cardiovascular occluder and methods of treating cardiovascular abnormalities by delivering the cardiovascular occluder.

Abstract: The invention provides a cardiovascular occluder for treating a cardiovascular abnormality comprising a frame and an alarmin or an alarmin activator bound to the surface of the frame. The invention further provides methods of manufacturing the cardiovascular occluder and methods of treating cardiovascular abnormalities by delivering the cardiovascular occluder.

Abstract: A system and method for implanting pellets into myocardial tissue for treatment of coronary artery restenosis, ischemic heart disease, or cardiac conduction of disturbances. The mechanism of delivery can be transcatheter via chambers of the heart, endoscopic pericardial approach via minimally invasive transthoracic access, or intraoperative pericardial approach during open-chest surgery. Noncardiac tissues can also be treated.

Abstract: A system and method for implanting pellets into myocardial tissue for treatment of coronary artery restenosis, ischemic heart disease, or cardiac conduction of disturbances. The mechanism of delivery can be transcatheter via chambers of the heart, endoscopic pericardial approach via minimally invasive transthoracic access, or intraoperative pericardial approach during open-chest surgery. Noncardiac tissues can also be treated.

Abstract: Implantable medical devices having an anti-restenotic coatings are disclosed. Specifically, implantable medical devices having coatings of peroxisome proliferator-activated receptor gamma (PPAR&ggr;) agonists are disclosed. The anti-restenotic PPAR&ggr; ligands include thiazolidinedione compounds including ciglitazone. The anti-restenotic medial devices include stents, catheters, micro-particles, probes and vascular grafts. The medical devices can be coated using any method known in the art including compounding the thiazolidinedione with a biocompatible polymer prior to applying the coating. Moreover, medical devices composed entirely of biocompatible polymer-thiazolidinedione blends are disclosed. Additionally, medical devices having a coating comprising at least one thiazolidinedione in combination with at least one additional therapeutic agent are also disclosed. Furthermore, related methods of using and making the anti-restenotic implantable devices are also disclosed.